Eye2Gene
Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging analysis with genomics to accelerate diagnosis of inherited retinal diseases for clinicians, pharmaceutical companies, and patients.
- Company typePrivate
- Founded-
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Eye2Gene does
Eye2Gene is an AI-powered precision ophthalmology platform that combines advanced retinal imaging analysis with genomic insights to accelerate diagnosis of inherited retinal diseases (IRDs). Created as a spinout from UCL and registered as Eye2Gene Ltd in England and Wales, the company serves ophthalmologists, retinal specialists, and medical geneticists seeking diagnostic certainty; pharmaceutical companies pursuing IRD gene therapies and clinical trial enrollment; and patients affected by the 270+ genes associated with IRDs. The platform analyses routine retinal imaging (OCT, FAF, IR) using proprietary machine learning algorithms to surface imaging biomarkers and ranked candidate gene lists, integrating with genetic sequencing data to identify causative mutations and shorten diagnostic timelines from years to weeks.
The core Eye2Gene Platform bundles AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarker capabilities, supported by a Secure Data Portal featuring AES-256 encryption, role-based access controls, and audit logging. Clinical credibility is anchored to validation on more than 3,000 genetically characterised IRD patients drawn from Moorfields Eye Hospital, the University of Oxford, and University Hospital Bonn, and to peer-reviewed publications in Nature Machine Intelligence (2025), the British Journal of Ophthalmology (2025), and Ophthalmology Science (2024, 2022). The product is classified as a Class IIa medical device under EU MDR 2017/745, is currently undergoing Notified Body conformity assessment for CE marking, with a parallel UKCA marking pathway, and is being developed under ISO 13485, ISO 14971, IEC 62304, and ISO 27001 frameworks.
Eye2Gene operates an enterprise go-to-market motion, distributing clinical decision support software through direct field sales to healthcare institutions and pharmaceutical companies on quote-based multi-year subscription contracts, with pricing not publicly disclosed. Marketing emphasis is on peer-reviewed research, conference presence (ISS 2025, Flower AI Summit 2025), and academic partnerships rather than paid acquisition. The company is privately held and backed by a mix of venture (TwinPath), angel (Cambridge Angels), technology transfer (UCLB), and UK government and innovation funders (InnovateUK, NIHR, UCL CDI, KQ Labs, Adeline). The leadership team comprises four co-founders: CEO Nikolas Pontikos, PhD; CTO Ismail Moghul, PhD; Chief AI Officer William Woof, PhD; and CMO Professor Michel Michaelides.
Eye2Gene firmographics
Firmographics- Name
- Eye2Gene
- Legal name
- Eye2Gene Ltd
- Website
- https://eye2gene.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging analysis with genomics to accelerate diagnosis of inherited retinal diseases for clinicians, pharmaceutical companies, and patients.
- Ownership category
- akta.pro rank
Eye2Gene industry classification
Industry- Product category
- AI-Powered Precision Ophthalmology Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
Keywords
Where Eye2Gene is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Eye2Gene business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Platform subscription/usage: Eye2Gene provides its AI-powered clinical decision support platform to healthcare institutions, pharma companies, and researchers. The platform is described as clinical decision support software not yet approved for clinical use. Revenue likely derives from platform licensing, subscription agreements, or usage-based pricing for institutional access, though specific commercial terms are not publicly disclosed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform access (quote-based) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Eye2Gene product offering
Product offeringCore offering
Eye2Gene is an AI-powered precision ophthalmology platform that analyzes routine retinal imaging (OCT, FAF, IR) combined with genomic data to support clinicians in diagnosing inherited retinal diseases (IRDs). The platform generates ranked candidate gene lists and quantitative imaging biomarkers to streamline genetic testing workflows, accelerating diagnosis from years to weeks and supporting clinical trial patient identification for pharmaceutical partners.
Product overview
Eye2Gene is an AI-powered precision ophthalmology platform combining advanced imaging analysis with genomic insights. The core Eye2Gene Platform integrates AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarkers to accelerate inherited retinal disease diagnosis from years to weeks. The platform is supported by a Secure Data Portal enabling secure cloud infrastructure with encrypted data storage for research, clinical collaboration, and clinical trial readiness.
Differentiator
Problem solved
Functional benefit
Products and services
- Eye2Gene Platform AI-powered clinical decision support platform that analyses routine retinal imaging (OCT, FAF, IR) combined with genomic sequencing data to assist clinicians, researchers, and pharmaceutical companies in diagnosing inherited retinal diseases (IRDs). Generates ranked candidate gene lists and quantitative imaging biomarkers to accelerate diagnosis from years to weeks and supports clinical trial patient identification.
Quantifiable outcome
- Diagnosis timeline reduced from years to weeks
- +2 more outcomes
Companies that use Eye2Gene
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Eye2Gene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Eye2Gene partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- UCL Institute of OphthalmologycoreFounding institution and primary research collaborator. Eye2Gene was created as a spinout from UCL. Ongoing collaboration on AI-powered inherited retinal disease diagnosis research, validation studies, and technology development.
- Moorfields Eye Hospital NHS Foundation TrustcoreLeading UK eye hospital and major clinical validation partner. Collaborating on clinical validation of Eye2Gene platform with genetically characterised IRD patient data. Key reference institution for clinical credibility.
- University of OxfordcoreClinical validation partner for Eye2Gene inherited retinal disease research. Collaborating on studies involving genetically characterised patients from Oxford.
- University Hospital BonncoreInternational clinical validation partner for Eye2Gene platform. Collaborating on inherited retinal disease studies with European patient populations.
- Sight Research UKmajorUK-based sight loss research charity. Collaborating on research into inherited retinal diseases and AI applications in ophthalmology.
- Retina UKmajorUK patient organisation for those affected by inherited retinal dystrophies. Collaborating on patient-focused research, webinars, and awareness activities.
- Stargardt ConnectedminorPatient advocacy group for Stargardt disease. Collaborating on patient engagement and community outreach.
- Moorfields Eye CharitymajorCharitable arm of Moorfields Eye Hospital supporting research and innovation in eye health. Supporting Eye2Gene research and development activities.
- NHS Genomic AI NetworkmajorNHS initiative supporting AI adoption in genomic medicine. Eye2Gene participates in NHS Clinical AI Interest Group activities for precision ophthalmology.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Eye2Gene competitors and assessment
Company assessmentDirect peers
- Digital Diagnostics (IDx-DR): Digital Diagnostics pioneered autonomous AI diagnostic software in ophthalmology (IDx-DR). Comparable as a regulatory-grade AI diagnostics platform targeting ophthalmic clinical workflows.
- RetinAI Medical: RetinAI builds AI tools (Discovery, iPredict) for OCT and fundus image analysis to support diagnosis and clinical trial recruitment in retinal disease. Directly comparable to Eye2Gene's imaging-based decision support and pharma patient-stratification focus.
- Eyenuk: Eyenuk develops FDA-cleared AI for retinal imaging (EyeArt for diabetic retinopathy). It is a direct peer to Eye2Gene in AI-based retinal disease detection, though focused on DR rather than IRDs.
Emerging players
- Voxeleron: Voxeleron provides OCT image analysis software and biomarkers for ophthalmic clinical research. Relevant peer in retinal image quantification that complements the imaging-analysis half of Eye2Gene's platform.
- AEYE Health: AEYE Health develops AI screening for diabetic retinopathy from retinal images, focused on primary care. Emerges as a peer in retinal AI diagnostics, overlapping with Eye2Gene's imaging-based triage/decision support value prop.
Others
- Tempus AI: Tempus builds multimodal AI combining imaging, genomic, and clinical data to inform precision medicine, including in ophthalmology. Adjacent enabling peer representing the broader precision-medicine AI infrastructure Eye2Gene's imaging-genomics model resembles.
- Genomics England / NHS Genomic Medicine Service: UK national genomics initiatives in inherited disease diagnosis. Adjacent ecosystem participant and potential buyer/partner for Eye2Gene's genetic prioritisation technology in the NHS pathway.
Broad incumbents
- Google Health (DeepMind Retina): DeepMind (Google Health) has published foundational AI work on OCT-based retinal disease detection. Broad incumbent peer representing the big-tech competitive threat in AI retinal diagnostics.
- Heidelberg Engineering: Heidelberg Engineering develops SPECTRALIS OCT and fundus imaging platforms widely used in retinal care. An incumbent imaging-device vendor whose hardware Eye2Gene's software analyses, and which itself markets image-analysis software for retinal disease.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a major ophthalmology device vendor (Cirrus OCT, Humphrey field analyser) with growing clinical software offerings. Broad incumbent comparable as the wider ophthalmology imaging/diagnostics ecosystem Eye2Gene operates in.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eye2Gene social profiles
Digital presenceEye2Gene compliance and trust
Trust signalCompliance7 records
Eye2Gene financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eye2Gene leadership team
Management profileNumber of profiles
Profiles5 records
Eye2Gene funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eye2Gene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eye2Gene
What does Eye2Gene do?
Eye2Gene is an AI-powered precision ophthalmology platform that analyzes routine retinal imaging (OCT, FAF, IR) combined with genomic data to support clinicians in diagnosing inherited retinal diseases (IRDs). The platform generates ranked candidate gene lists and quantitative imaging biomarkers to streamline genetic testing workflows, accelerating diagnosis from years to weeks and supporting clinical trial patient identification for pharmaceutical partners.
Is Eye2Gene a public or private company?
Eye2Gene is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eye2Gene founded?
Eye2Gene was founded in -1. It employs 1 to 10 people.
Where is Eye2Gene based?
Eye2Gene is headquartered in London, United Kingdom, in the Europe region.
How does Eye2Gene make money?
One revenue line is on record: platform subscription/usage.
Who are Eye2Gene's main competitors?
Direct peers on record are Digital Diagnostics (IDx-DR), RetinAI Medical and Eyenuk. Emerging players are Voxeleron and AEYE Health. Others are Tempus AI and Genomics England / NHS Genomic Medicine Service. Broad incumbents are Google Health (DeepMind Retina), Heidelberg Engineering and Carl Zeiss Meditec.
Does Eye2Gene have an API?
No public API is recorded for Eye2Gene.
What industry is Eye2Gene in?
Eye2Gene's product category is AI-Powered Precision Ophthalmology Software. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 3851.